Author: Global Newswire

Vittoria Biotherapeutics Completes $25 Million In Private Financing To Propel Groundbreaking Cell Therapy Candidates

November 12, 2024

PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) — Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced the successful completion of a $25 million private financing round. This funding is a $10 million extension to its previous $15 million financing secured in November 2023. The latest […]

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

December 7, 2023

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma. “The […]

Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV

August 30, 2021

Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the Temple University team collaborating with Excision on a project, CRISPR for Cure, has received a Martin Delaney Grant from the National Institutes of Health (NIH) of $4.8 million on an annual basis for the next five years […]